| Mir-34: a new weapon against cancer? G Misso, MT Di Martino, G De Rosa, AA Farooqi, A Lombardi, V Campani, ... Molecular therapy-nucleic acids 3, 2014 | 546 | 2014 |
| Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Clinical cancer research 18 (22), 6260-6270, 2012 | 247 | 2012 |
| Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullà, M Rossi, ... Clinical Cancer Research 19 (8), 2096-2106, 2013 | 207 | 2013 |
| miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ... Journal of cellular physiology 228 (7), 1506-1515, 2013 | 192 | 2013 |
| miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ... Cell death & disease 3 (11), e436-e436, 2012 | 177 | 2012 |
| DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma N Amodio, M Leotta, D Bellizzi, MT Di Martino, P D'Aquila, M Lionetti, ... Oncotarget 3 (10), 1246, 2012 | 159 | 2012 |
| In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma MT Di Martino, A Gullà, MEG Cantafio, M Lionetti, E Leone, N Amodio, ... Oncotarget 4 (2), 242, 2013 | 153 | 2013 |
| In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma MT Di Martino, V Campani, G Misso, ME Gallo Cantafio, A Gulla, ... PloS one 9 (2), e90005, 2014 | 131 | 2014 |
| A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells T Calimeri, E Battista, F Conforti, P Neri, MT Di Martino, M Rossi, ... Leukemia 25 (4), 707-711, 2011 | 125 | 2011 |
| Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo P Tassone, MT Di Martino, M Ventura, A Pietragalla, I Cucinotto, ... Cancer biology & therapy 8 (7), 648-653, 2009 | 116 | 2009 |
| Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ... Leukemia 29 (11), 2173-2183, 2015 | 113 | 2015 |
| Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity L Raimondi, N Amodio, MT Di Martino, E Altomare, M Leotta, ... Oncotarget 5 (10), 3039, 2014 | 113 | 2014 |
| Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic “dark matter” K Grillone, C Riillo, F Scionti, R Rocca, G Tradigo, PH Guzzi, S Alcaro, ... Journal of Experimental & Clinical Cancer Research 39 (1), 1-19, 2020 | 111 | 2020 |
| Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma D Cosco, F Cilurzo, J Maiuolo, C Federico, MT Di Martino, MC Cristiano, ... Scientific reports 5 (1), 17579, 2015 | 111 | 2015 |
| miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells N Amodio, D Bellizzi, M Leotta, L Raimondi, L Biamonte, P D’Aquila, ... Cell Cycle 12 (23), 3650-3662, 2013 | 109 | 2013 |
| Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A Gullà, ... Oncotarget 6 (29), 27343, 2015 | 104 | 2015 |
| Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia M Lionetti, P Musto, MT Di Martino, S Fabris, L Agnelli, K Todoerti, ... Clinical cancer research 19 (12), 3130-3142, 2013 | 102 | 2013 |
| A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells A Gulla, MT Di Martino, ME Gallo Cantafio, E Morelli, N Amodio, C Botta, ... Clinical cancer research 22 (5), 1222-1233, 2016 | 101 | 2016 |
| A p53‐dependent tumor suppressor network is induced by selective miR‐125a‐5p inhibition in multiple myeloma cells M Leotta, L Biamonte, L Raimondi, D Ronchetti, MT Di Martino, C Botta, ... Journal of cellular physiology 229 (12), 2106-2116, 2014 | 101 | 2014 |
| Promises and challenges of MicroRNA-based treatment of multiple myeloma P Tagliaferri, M Rossi, M T Di Martino, N Amodio, E Leone, A Gulla, A Neri, ... Current cancer drug targets 12 (7), 838-846, 2012 | 98 | 2012 |
